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Highlights
• Because  biomedical  scent  detection  is  a
potential tool to identify diseases, in the eyes of
regulatory bodies it is comparable to a health
technology.
• This is the ;rst report evaluating the canines’
sense  of  smell  from  the  point  of  view  of  a
health technology. 
•  It is important for researchers to be aware of
the  required  regulatory  controls  before  dogs
can have an accredited role in the clinic.
• We  discuss  the  current  advantages  and
disadvantages  of  the  method  to  help  guide
researchers towards a<ainable goals. 
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Abstract
Biomedical scent detection dogs identify the scent pro;les of diseases, such as cancer, 
diabetes or pathogenic micro-organisms.  What the ;eld of biomedical scent detection 
has been lacking, however, is the assessment of the method from the point of view of a 
health technology. All health technologies undergo a thorough evaluation of safety, 
clinical e:ectiveness and costs, as well as ethical, social, organizational and legal 
evaluations in some cases. Passing these regulatory controls is a pre-requisite before a 
technology is approved for use in decision-making about patient outcomes. Biomedical 
scent detection has a lot of a<ractive qualities, such as the sensitivity and speci;city of 
the dogs’ noses, safety and relative cost-e:ectiveness. However, the method also has 
various challenges, in particular regarding its clinical e:ectiveness. The most pertinent 
issues to address before the dogs would pass as a health technology are 
standardization of the training techniques, both intra- and inter-dog reproducibility, 
and generalization of the detection task to the early stages of disease progression. We 
recommend se<ing realistic goals in terms of what the dogs can and cannot do and 
adopting a collaborative approach between clinicians and animal psychophysicists.
INTRODUCTION
Canines’ sense of smell has been utilized successfully
for a long time for di:erent purposes, such as detection
of explosives, narcotics, and bed bugs, to name just a
few.  Biomedical  scent  detection  (or  medical  scent
detection) is an emerging method that uses the canine
olfactory capacity for identifying the scent pro;les of
diseases, such as di:erent types of cancers (Moser and
McCulloch  2010;  Jezierski  et  al.  2015),  diabetes
(Gadbois and Reeve 2014; Hardin et al.   2015) or the
presence of pathogenic micro-organisms (Bomers et al.
2014; Bryce et al. 2017; Koivusalo et al. 2017; Koskinen
et al. 2017).  It is the combination of the acuity of the
sense  of  smell  with  the  ability  to  learn  by  operant
conditioning that makes dogs potential biodetectors for
di:erent  tasks  (Pirrone  and  Albertini  2017).  The
ultimate goal in most cases is to involve dogs as a fast
method for the diagnosis or screening of human patient
disease.  Research  studies  illustrate  that  dogs  are
capable  of  distinguishing  the  volatile  organic
compounds characteristic of diseases (Rudnicka et  al.
2014).  An  important  topic  to  take  into  consideration
when training and testing dogs for  this  purpose is  a
comparison  with  conventional  technologies  used  in
screening and diagnosis.  If a dog’s indication is to be
used  in  making  decisions  on  a  patient’s  health  and
treatment  outcomes,  canine scent  detection would be
comparable to a health technology in the eyes of health
organizations  and regulatory  bodies.  The  purpose  of
this  review it  to  evaluate canine scent  detection as  a
medical  device,  to  assess  whether  it  would  pass  a
health  technology  assessment  (HTA)  as  it  currently
stands  and  what  the  most  pertinent  technical
challenges are.
DEFINITION AND QUALITY ASSESSMENT OF
HEALTH TECHNOLOGIES
The  World  Health  Organization  (WHO)  de;nes  a
health technology as (World Health Organization 2018):
“A health  technology  is  the  application  of  organized
knowledge and skills in the form of devices, medicines,
vaccines, procedures and systems developed to solve a
health problem and improve quality of lives.” 
Amongst  the  di:erent  technologies,  the  dog’s  nose
could  be  categorized  as  a  medical  device:  a  highly
sensitive,  built-in  olfactory  detection  system  used  to
identify diseases. However, before a medical device or
any health technology is granted permission for oIcial
clinical use in any country, an approval is required by
national health organizations, such as Food and Drug
Administration (FDA) in the US. The requirements for
approval  include  passing  several  regulatory  controls
(US  Food and Drug  Administration,  2018)  that  set  a
high standard for all health technologies.
HEALTH  TECHNOLOGY  ASSESSMENT  (HTA)
IS AN EVALUATION TOOL
A practical  tool  for  evaluating  the  quality  of  health
technologies is a process known as Health Technology
Assessment  (HTA),  which  uses  scienti;c  research  to
inform decision-makers on the introduction and use of
a health technology. Each country’s regulatory bodies
implement  HTA in  their  own  way,  but  international
organizations  have  set  guidelines  for  the  process
(EUnetHTA  Core  Model®  2016;  Health  Technology
Assessment International  2018;  International  Network
of Agencies for Health Technology Assessment 2018). 
The aspects to be evaluated depend on the technology
in  question  and  the  assessing  regulatory  body.  The
following  information,  which  is  pertinent  also  to
biomedical scent detection, is always asked: 
• Description  of  the  health  problem  and
currently available technology for solving it.  
• Technical description of the new technology in
detail.
• Clinical e:ectiveness: Does the new technology
work  equally  well  or  be<er  than  a  standard
method  currently  in  use?  The  requirement
before granting a permission for marketing is
to demonstrate that the technology is at  least
“substantially  equivalent”  (FDA) to  a  current
standard technology.
• Safety: The technology has to be safe not only
for  the  patients  but  also  for  the  people
operating  it.  Potential  risks  and  harms  are
assessed  that  will  determine  the  risk
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classi;cation of the technology.
• Economic  evaluation:  Value-for-money
assessment is conducted to evaluate the costs
and  bene;ts  of  the  technology  in  relation  to
health-related  outcomes  as  well  as  the
economic burden on the healthcare system and
society. 
• Ethical, social, organizational and legal aspects
may also be evaluated. 
HOW DOES BIOMEDICAL SCENT DETECTION
RANK  IN  EVALUATION  OF  THE  MOST
FUNDAMENTAL CRITERIA?
CLINICAL EFFECTIVENESS
If we ask whether dogs can smell cancer or a pathogen,
the answer would be a ‘yes’, as dogs can detect diseases
with  very  high  levels  of  sensitivity  and  speci;city
(Jezierski  et  al.  2015).   But  to  assess  the  clinical
e:ectiveness of the technology the question is: can dogs
do it with the same reproducibility and accuracy as an
analytical  instrument already in use,  and can patient
treatment  outcomes  be  planned  on  the  basis  of  the
results? 
To be approved by health organizations, several aspects
need  to  be  addressed  before  the  answer  is  ‘yes’ for
canine scent detection (Fig. 1). 
Here  are  some  of  the  main  challenges  that  scent
detection researchers are trying to solve: 
1) Standardization of the Training and Testing Methods 
Currently there is no standardized way to train and test
the  dogs,  which  leads  to  variability  in  results  (as
discussed by Elliker  et  al.  2014;  Jezierski  et  al.  2015;
Gadbois & Reeve, 2016). Traditionally dogs have been
trained and tested using an alternative  forced  choice
(AFC)  method,  where  a  line-up  or  a  scent  wheel
contains one target scent (S+, here, a “disease odour”)
and  several  non-target  or  distractor  scents  (S–,  a
healthy control odour), and then running double-blind
trials,  where  neither  the  dog  nor  the  dog  handler
knows the sample positioning and the dog is required
to locate and indicate the target, diseased, odour. This
method is  appropriate  for  a  proof-of-principle  study,
but in a real screening situation the number of S+ and
S– samples is unknown. If the dog has been trained to
always ;nd one ‘win’ in a line-up, what happens in a
screening situation? 
Studies have shown that when dogs were trained using
the AFC task of one S+ and four S– samples, and then
tested with randomized numbers of S+ and S– samples,
the  sensitivity  and  speci;city  of  their  performance
deteriorated  signi;cantly  (Amundsen  et  al.  2014;
Hackner et al. 2016). This illustrates the importance of
training and testing the dogs with randomized samples
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Figure 1. Evaluation of Biomedical Scent Detection as a Health 
Technology
as early in the process as possible.
The  AFC  method  also  has  a  disadvantage  due  to  a
memory  load  it  may  impose  on  the  detection  dog.
Gadbois  and  Reeve  (Gadbois  and  Reeve  2014;  2016)
have  shown  that  the  accuracy  of  canines  decreases
signi;cantly the further down the target is in the line-
up because of a tax on the dogs’ memory processing.
The goal of biomedical scent detection is to assess the
sensory-perceptual  abilities  of  dogs  to  distinguish
scents extremely similar  to each other, and not make
the  process  a  memory  load  task  of  a  past  event.
Therefore,  to  avoid  the  tax  on  memory,  the  use  of
discrimination  tasks  of  2  or  3  choices  is  more
favourable (Gadbois and Reeve 2014; 2016; Koivusalo et
al.  2017).  An  even  more  elegant  solution  is  a  pure
detection task, i.e. a yes/no, go/no-go system, where the
dog is presented with one stimulus at  a  time,  which
requires  a  ‘yes’ or  ‘no’ answer  (Gadbois  and  Reeve
2014, 2016). In this approach the dog always gets a win
and the  task  is  a  pure  sensory  task,  which increases
accuracy. 
2) Reproducibility
An analytical laboratory instrument analyzes hundreds
of samples daily with high accuracy and throughput,
albeit  a  certain degree of variability (as discussed by
Moser & McCulloch 2010). Dogs cannot be considered
as instruments, and they will never obtain an accuracy
of 100% due to their own inherent variability (Hackner
and  Pleil  2017).  Furthermore,  the  published  medical
scent detection studies are di:erent from real screening
situations,  where  larger  sets  of  samples  would  be
processed daily, and the reproducibility will be harder
to accomplish. This stems from several factors:
The work of an ‘analytical’ dog is highly repetitive, and
it can be diIcult to keep up their motivation, as dogs
are  subject  to  boredom,  fatigue  and  external
distractions. The job of these dogs is di:erent from the
scent detection work in the ;eld (e.g. drugs, explosives,
search and rescue), where the dogs get to use more of
their natural ‘hunting’ behaviors and the task remains
more of a game to them. 
In  contrast  to  laboratory  devices,  dogs  may  try  and
change  their  strategies  in  order  to  be  rewarded  at
minimum e:ort leading to inaccuracies during double-
blind trials.
The  handler’s  positive  and  negative  sensations  are
easily transmi<ed to the dogs. 
Also,  in  contrast  to  analytical  devices  that  detect
compounds very speci;cally, each individual dog can
perceive complex scent pa<erns di:erently leading to
variability between di:erent dogs.  Finding dogs with
an ability to generalize  the complex detection task is
important. 
3) Detection of Diseases in True Unknown Samples
Most  published  studies  have  been  performed  with
samples from already diagnosed patients. However, it
is crucial to improve the overall survival: earlier cancer
detection may permit earlier intervention and detection
of  colonization  by  a  pathogen  prior  to  an  actual
infection may enable early treatment and containment
as well. Therefore, the next step aTer standardization of
training/testing  methods  is  to  obtain  results  with
completely unknown samples. 
It  is  likely  that  the  scent  pro;le  changes  between
samples from patients with an advanced vs. an earlier
stage  of  disease.  Amundsen  et  al.  (Amundsen  et  al.
2014)  showed  that  the  dogs’ performance  is  a:ected
when they are tested with patients suspected to have
di:erent stages and forms of lung cancer. This ;nding
highlights the importance of training the dogs not only
with  samples  from  patients  with  an  advanced  or
malignant disease but with samples from benign stages
of disorders.
To  teach  the  dogs  the  subtle  discrimination  among
di:erent stages of a disease may not be a trivial task, as
what truly is a positive sample and what is a negative
one  can  turn  out  to  be  a  grey  area.   This  is  where
drawing realistic cut-o:s for what dogs can and cannot
do should be considered. 
4) Sample presentation 
One experimental factor to consider and standardize is
the  way  the  biological  samples  are  presented  and
preserved (Hackner and Pleil 2017; Reeve et al. 2017).
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Also  the  protocol  used  (or  not  used)  to  clean  and
handle  the  scent  containers  between  trials  di:ers
widely,  but  ultimately  the  goal  is  that  the  dogs
discriminate the target scent amongst any background
scent. What is important to acknowledge in biomedical
scent detection is that the dog is constantly learning to
discriminate  subtle  di:erences  between samples,  and
without due diligence they may accidentally learn to
indicate  something  superUuous  or  superstitious.  To
circumvent  this,  many  researchers  se<le  for  a  set
cleaning protocol or using disposable scent containers
only  (Jezierski  et  al.  2015;  Koivusalo  et  al.  2017;
Koskinen et al. 2017). 
SAFETY 
This  is  one of  most  a<ractive qualities  of  biomedical
scent detection: it  is very non-invasive in nature, and
therefore  safe  for  the  patients.  For  some  patients  a
physical interaction with animals may be a concern, but
if the detection work takes place in a laboratory, there is
no need for contact between the patients and the dogs.
An  important  risk  assessment  to  be  made  is  the
evaluation of  the consequences of  false  positive (dog
indicates an S– sample) and false negative (dog does
not  indicate  S+)  results.  False  negative  results  would
impose  a  more  serious  safety  concern,  as  it  would
involve missing patients at risk. 
COST EVALUATION
Another  appealing  quality  of  biomedical  scent
detection is its potential to be more cost-e:ective than
many  expensive  laboratory  methods.  For  example,
Arnaud (2016) determined that biopsy-based methods
of non-small cell lung cancer biomarker testing can cost
upwards  of  $2,500.  The  analysis  of  volatile  organic
compounds  (VOCs,  Amann  et  al.  2014)  in  exhaled
breath  samples  is  a  much  less  expensive,  and  less
invasive  procedure,  and  has  proven  a  promising
avenue  for  cancer  diagnosis  (Shirasu  and  Touhara,
2011).  The  analytical  techniques  used  to  identify
disease-speci;c  VOCs,  such  as  SPME  and  GC-MS,
however,  can  be  expensive  and  extensive  training  is
required  to  perform  the  analysis  and  analyze  the
results (Shirasu and Touhara, 2011). 
Alternatively,  the  identi;cation  of  diseased  breath
samples by detection dogs requires minimal equipment
and the analysis (interpretation of the dogs’ indication
behaviour),  is  straight  forward (Jezierski  et  al.  2015).
McCulloch et al.  (2006) examined canine detection of
non-small cell  lung cancer in donated breath samples
and  showed  that  the  dogs  were  99%  sensitive  and
speci;c, providing evidence for a highly promising yet
cheaper  detection  system.  Also,  dogs  would  be  a
rational solution in areas where high-tech instrument-
based  analysis  is  unavailable  (Rooney  et  al.  2013;
Jezierski et al. 2015) 
The disadvantage is that the process of training a dog is
a  time-consuming  and  hence  a  money-consuming
process because it can take up to a year to train a dog;
fully  trained  medical  alert  dogs  can  cost  anywhere
between $8000 - $20,000 USD (beyondtype1.org). Even
then,  it  does  not  mean  that  every  individual  dog  is
suitable for the task, and even at later stages of testing,
some dogs may not show the desired sensitivity and
speci;city (Jezierski et al. 2015). 
CONCLUSION
To be approved as a clinically valid health technology
by  regulatory  bodies,  biomedical  scent  detection  has
not reached the required standard yet. Whether it will,
depends on the crucial research that needs to be done.
In  the  current  age  of  high-tech  medical  devices
competing in the market,  se<ing a realistic  target for
the canines might speed up the process as it is a race of
who has the most clinically e:ective and cost-e:ective
method  ;rst.  In  order  to  make  biomedical  scent
detection a reliable health technology, understanding of
the canine olfactory learning processes is needed both
through  a  clinical  research  and  psychophysical
approach. 
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